Date | Price Target | Rating | Analyst |
---|---|---|---|
1/19/2022 | $7.00 | Buy | Maxim Group |
8/18/2021 | $5.75 → $5.25 | Buy | Roth Capital |
4 - INVO Bioscience, Inc. (0001417926) (Issuer)
4 - INVO Bioscience, Inc. (0001417926) (Issuer)
4 - INVO Bioscience, Inc. (0001417926) (Issuer)
Maxim Group initiated coverage of INVO Bioscience with a rating of Buy and set a new price target of $7.00
Roth Capital reiterated coverage of INVO Bioscience with a rating of Buy and set a new price target of $5.25 from $5.75 previously
SARASOTA, Fla., July 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Barbara Levy, M.D., FACOG, FACS as the Company's Senior VP, Global Clinical Integration. Dr. Levy is considered one of the most influential clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee.
SARASOTA, Fla., June 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced the appointment of Andrea Goren as the Company's chief financial officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers
SARASOTA, Fla., May 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, is pleased to announce the appointment of tenured women's health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company. Chamberlain brings over 15 years of marketing experience in the women's health field includi
-SEC Filing
INVO Bioscience (NASDAQ:INVO) reported quarterly losses of $(0.42) per share. The company reported $1.58 million in sales this quarter. This is a 352.84 percent increase over sales of $348.02 thousand the same period last year.
8-K - INVO Bioscience, Inc. (0001417926) (Filer)
8-K - INVO Bioscience, Inc. (0001417926) (Filer)
8-K - INVO Bioscience, Inc. (0001417926) (Filer)
SC 13G/A - INVO Bioscience, Inc. (0001417926) (Subject)
SC 13G/A - INVO Bioscience, Inc. (0001417926) (Subject)
SC 13G - INVO Bioscience, Inc. (0001417926) (Subject)
SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the second quarter 2024 for the period ended June 30, 2024 and provided a business update. Q2 2024 Financial Highlights (all metrics compared to Q2 2023 unless otherwise noted) Revenue was $1,836,597, an increase of 481% compared to $315,902. Revenue increased 17% sequentially compared to Q1 2024.
SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provided a business update. Q1 2024 Financial Highlights (all metrics compared to Q1 2023 unless otherwise noted) Revenue was $1,576,286, an increase of 353% compared to $348,025.Clinic revenue increased 417% to $1,537,199, compared to $297,381. All reported
SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update. Q4 2023 Financial Highlights (all metrics compared to Q4 2022 unless otherwise noted) Revenue was $1,381,754, an increase of 397% compared to $278,142.Clinic revenue increased 519% to $1,362,938,
Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its first quarter 2023, for the period ended March 31, 2023, after the market close on Monday, May 15, 2023. The Company has scheduled a conference call that same day, Monday, May 15, 2023, at 4:30 pm ET, to review the results.